Literature DB >> 15813851

Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.

Jonathan Cohen1, Minal Gandhi, Paru Naik, David Cubitt, Kanchan Rao, Urvashi Thaker, E Graham Davies, H Bobby Gaspar, Persis J Amrolia, Paul Veys.   

Abstract

The incidence of Epstein-Barr virus (EBV) viraemia and lymphoproliferative disease (LPD) was studied in a consecutive cohort of 128 paediatric patients undergoing stem cell transplantation (SCT) with reduced-intensity conditioning (RIC; n = 65) or conventional-intensity conditioning (CIC; n = 68). Following CIC, six of 68 (8%) developed viraemia; all remained asymptomatic. EBV viraemia (23 of 65 patients = 35%, P < 0.001) and LPD (10 of 65 = 15%, P < 0.001) were significantly more frequent following RIC. Of the 23 RIC patients who developed viraemia, eight remained asymptomatic, five had symptomatic viraemia (fever +/- rash), and 10 patients developed LPD, two of whom died. An absolute lymphocyte count of <0.3 x 10(9)/l at the time of onset of viraemia was strongly predictive of development of LPD (P < 0.05) in this group. The incidence of viraemia was significantly higher in patients receiving serotherapy with antithymocyte globulin (ATG; 15 of 43, 35%) than Campath (12 of 73, 16.4%, P < 0.05). Primary immunodeficiency and acute graft-versus-host disease were associated with EBV viraemia in univariate analysis, but were not independent risk factors. In conclusion, EBV viraemia and LPD appear to be significantly more common in children following RIC SCT, particularly with selective depletion of recipient T cells relative to B cells following the use of ATG. This probably reflects the profound immunosuppression following RIC SCT, together with the incomplete ablation of recipient-derived B cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813851     DOI: 10.1111/j.1365-2141.2005.05439.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Epstein-Barr virus infection after unrelated cord blood transplantation: reactivation or reinfection?

Authors:  Keisei Kawa; Akihisa Sawada; Maho Koyama; Masami Inoue
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

Review 2.  T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Authors:  Catherine M Bollard; Cliona M Rooney; Helen E Heslop
Journal:  Nat Rev Clin Oncol       Date:  2012-07-17       Impact factor: 66.675

3.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

Authors:  Claudio G Brunstein; Daniel J Weisdorf; Todd DeFor; Juliet N Barker; Jakub Tolar; Jo-Anne H van Burik; John E Wagner
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Michael Uhlin; Helena Wikell; Mikael Sundin; Ola Blennow; Markus Maeurer; Olle Ringden; Jacek Winiarski; Per Ljungman; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

5.  Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.

Authors:  Phillip Scheinberg; Steven H Fischer; Li Li; Olga Nunez; Colin O Wu; Elaine M Sloand; Jeffrey I Cohen; Neal S Young; A John Barrett
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

6.  A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Authors:  Doris M Ponce; Craig Sauter; Sean Devlin; Marissa Lubin; Anne Marie Gonzales; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Jenna D Goldberg; Guenther Koehne; Miguel A Perales; James W Young; Hugo Castro-Malaspina; Ann Jakubowski; Esperanza B Papadopoulos; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

Review 7.  Bone marrow transplantation in Schimke immuno-osseous dysplasia.

Authors:  Alireza Baradaran-Heravi; Jonas Lange; Yumi Asakura; Pierre Cochat; Laura Massella; Cornelius F Boerkoel
Journal:  Am J Med Genet A       Date:  2013-08-15       Impact factor: 2.802

8.  Bacteremia during neutropenic episodes in children undergoing hematopoietic stem cell transplantation with ciprofloxacin and penicillin prophylaxis.

Authors:  Worawut Choeyprasert; Suradej Hongeng; Usanarat Anurathapan; Samart Pakakasama
Journal:  Int J Hematol       Date:  2016-10-22       Impact factor: 2.490

9.  Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

Authors:  Anne H Blaes; Qing Cao; John E Wagner; Jo-Anne H Young; Daniel J Weisdorf; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-14       Impact factor: 5.742

10.  EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases.

Authors:  J Sanz; M Arango; L Senent; I Jarque; P Montesinos; A Sempere; I Lorenzo; G Martín; F Moscardó; E Mayordomo; M Salavert; C Cañigral; B Boluda; C Salazar; J L López-Hontangas; M A Sanz; G F Sanz
Journal:  Bone Marrow Transplant       Date:  2013-12-02       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.